Transmedics Group Inc [TMDX] stock is trading at $115.68, up 2.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The TMDX shares have gain 2.39% over the last week, with a monthly amount drifted -3.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on October 13, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $145. Previously, Evercore ISI started tracking the stock with Outperform rating on September 16, 2025, and set its price target to $155. On September 04, 2025, Stifel initiated with a Hold rating and assigned a price target of $115 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $75 on December 17, 2024. Needham downgraded its rating to a Hold. Oppenheimer reiterated a Outperform rating for this stock on October 29, 2024, and downed its price target to $125. In a note dated October 29, 2024, Needham reiterated a Buy rating on this stock and revised its target price from $208 to $109.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $145.50 over the past year. Currently, Wall Street analysts expect the stock to reach $150 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $115.68 at the most recent close of the market. An investor can expect a potential return of 29.67% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 531.29M for the trailing twelve months, which represents a growth of 37.68%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.28 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 111.52 points at the first support level, and at 107.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 119.18, and for the 2nd resistance point, it is at 122.67.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 9.86. On the other hand, the Quick Ratio is 9.17, and the Cash Ratio is 7.07. Considering the valuation of this stock, the price to sales ratio is 7.42, the price to book ratio is 12.38 and price to earnings (TTM) ratio is 59.82.
Transactions by insiders
Recent insider trading involved Hassanein Waleed H, President & CEO, that happened on Aug 06 ’25 when 8400.0 shares were purchased. President & CEO, Hassanein Waleed H completed a deal on Aug 07 ’25 to buy 8475.0 shares. Meanwhile, Director Basile Edward M sold 4143.0 shares on Aug 04 ’25.
